CFO4Life Group’s Biogen BIIB Stock Holding History

CFO4Life Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,213	Closed	-$332K	–	88
2017 Q1	$332K	Buy	+1,213	New	+$343K	0.3%	62

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CFO4Life Group's BIIB Position: Q2 2017 in Review

CFO4Life Group sold out of Biogen (BIIB) in Q2 2017, closing a stake of 1,213 shares — an estimated $332K sold.

CFO4Life Group first reported a position in BIIB in Q1 2017 and held it in 1 quarter. The position peaked at $332K in Q1 2017. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

CFO4Life Group reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
CFO4Life Group sold 1,213 Biogen shares in Q2 2017, an estimated $332K.
CFO4Life Group first reported a position in Biogen in Q1 2017 and held it in 1 quarter.
CFO4Life Group's Biogen position peaked at $332K in Q1 2017.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on CFO4Life Group's 13F filing for Q2 2017, filed 8 Aug 2017.